Optimizing the clinical pharmacology of tuberculosis medications.

@article{Egelund2015OptimizingTC,
  title={Optimizing the clinical pharmacology of tuberculosis medications.},
  author={Eric Free Egelund and Abdullah Saleh Alsultan and Charles A Peloquin},
  journal={Clinical pharmacology and therapeutics},
  year={2015},
  volume={98 4},
  pages={387-93}
}
Tuberculosis (TB) treatment has changed little in the past 40 years. The current standard therapy requires four drugs for 2 months followed by two drugs for 4 months. This "short-course" regimen is not based on optimized pharmacokinetic and pharmacodynamic properties, but empiric evidence. A review of existing data suggests that pharmacokinetic variability with isoniazid and rifampin is greater than previously thought, and that efficacy is not as good as traditionally reported. Adding new drugs… CONTINUE READING

1 Figure or Table

Connections & Topics

Mentioned Connections BETA
This article reviews the current potential of the first - line TB drugs ( rifamycins , isoniazid , pyrazinamide , and ethambutol ) as well as the fluoroquinolones to introduce a true short - course TB regimen .
This article reviews the current potential of the first - line TB drugs ( rifamycins , isoniazid , pyrazinamide , and ethambutol ) as well as the fluoroquinolones to introduce a true short - course TB regimen .
This article reviews the current potential of the first - line TB drugs ( rifamycins , isoniazid , pyrazinamide , and ethambutol ) as well as the fluoroquinolones to introduce a true short - course TB regimen .
This article reviews the current potential of the first - line TB drugs ( rifamycins , isoniazid , pyrazinamide , and ethambutol ) as well as the fluoroquinolones to introduce a true short - course TB regimen .
This article reviews the current potential of the first - line TB drugs ( rifamycins , isoniazid , pyrazinamide , and ethambutol ) as well as the fluoroquinolones to introduce a true short - course TB regimen .
This article reviews the current potential of the first - line TB drugs ( rifamycins , isoniazid , pyrazinamide , and ethambutol ) as well as the fluoroquinolones to introduce a true short - course TB regimen .
A review of existing data suggests that pharmacokinetic variability with isoniazid and rifampin is greater than previously thought , and that efficacy is not as good as traditionally reported .
A review of existing data suggests that pharmacokinetic variability with isoniazid and rifampin is greater than previously thought , and that efficacy is not as good as traditionally reported .
All Topics